Gilead Sciences GILD
NASDAQ GILD
$143.72 -1.09 (-0.75%)
As of: Sep 11, 2026 · 3:59 PM EDT

Gilead Sciences (GILD) Revenue (QoQ) (2009 - 2026)

Analysis

Gilead Sciences (GILD) Revenue (QoQ) (2009 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Amgen 203.97 Bn 189.99 Bn 7.24 Bn
2 Gilead Sciences 178.74 Bn 175.56 Bn 6.22 Bn
3 Vertex Pharmaceuticals 130.73 Bn 122.88 Bn 2.84 Bn
4 Regeneron Pharmaceuticals 80.42 Bn 72.42 Bn 3.93 Bn
5 Argenx Se 60.40 Bn 55.21 Bn 1.37 Bn
6 Moderna 57.65 Bn 52.52 Bn 52.00 Mn
7 Alnylam Pharmaceuticals 33.37 Bn 30.07 Bn 992.69 Mn
8 Biogen 32.15 Bn 30.86 Bn 1.96 Bn
9 Roivant Sciences 29.58 Bn 29.58 Bn 1.16 Mn
10 Insmed 28.06 Bn 26.90 Bn 358.27 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 12.11%
Mar 31, 2026 -12.18%
Dec 31, 2025 2.01%
Sep 30, 2025 9.70%
Jun 30, 2025 6.22%
Mar 31, 2025 -11.92%
Dec 31, 2024 0.32%
Sep 30, 2024 8.50%
Jun 30, 2024 4.01%
Mar 31, 2024 -6.02%
Dec 31, 2023 0.89%
Sep 30, 2023 6.85%
Jun 30, 2023 3.89%
Mar 31, 2023 -14.03%
Dec 31, 2022 4.93%
Sep 30, 2022 12.49%
Jun 30, 2022 -5.01%
Mar 31, 2022 -9.03%
Dec 31, 2021 -2.39%
Sep 30, 2021 19.37%